Johnson & Johnson has asked U.S. regulators to allow booster shots of its COVID-19 vaccine as the U.S. government moves toward shoring up protection in more vaccinated Americans.
J&J says it filed data with the Food and Drug Administration on giving a booster dose between two to six months after vaccination. The U.S. government last month authorized booster doses of Pfizer’s vaccine in vulnerable groups.
A panel of FDA advisers meets next week to consider boosters for both J&J and Moderna vaccines. It’s part of a sweeping effort by the Biden administration to boost protection amid the Delta variant and potential waning of vaccine strength.
The FDA is convening its outside panel of advisers next week to review booster data from both J&J and Moderna. It’s the first step in a review process that also includes sign-off from the leadership of both the FDA and the Centers for Disease Control and Prevention. If both agencies give the go-ahead, Americans could begin getting J&J and Moderna boosters later this month.
More health care and Big Pharma coverage from Fortune:
- Five biggest myths about the COVID-19 vaccines, debunked
- CVS Health is about to turn hundreds of its drugstores into health care super-clinics
- Why Instacart’s new CEO is also launching a women’s health startup
- China, one of the world’s few “COVID-zero” holdouts, sets a loose timeline for easing virus measures
- New Zealand admits it can no longer keep COVID out of its borders
Subscribe to Fortune Daily to get essential business stories straight to your inbox each morning.